ArticleP & T : a peer-reviewed journal for formulary management2018
Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review.
Article in P & T : a peer-reviewed journal for formulary management, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Gestational Breast Cancer - a Review of Outcomes, Pathophysiology, and Model Systems.Journal of mammary gland biology and neoplasia · 2023Review
- Safety and management of niraparib monotherapy in ovarian cancer clinical trials.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Review
- Cancer and Pregnancy: A Comprehensive Review.Cancers · 2021Review
- Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells.International journal of molecular sciences · 2021Article
- Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors DecreaseFrontiers in immunology · 2021Article
- Is It Possible to Personalize the Diagnosis and Treatment of Breast Cancer during Pregnancy?Journal of personalized medicine · 2020Review
- Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.Cancers · 2020Review
- Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.ACS medicinal chemistry letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review the pharmacology, safety, efficacy, and role of poly adenosine diphosphate [ADP]-ribose polymerase (PARP) inhibitors in the treatment and maintenance of relapsed, advanced ovarian cancer. SUMMARY: A total of 3 phase 2 trials and 2 phase 3 trials were reviewed that evaluated the safety and efficacy of oral niraparib, olaparib, and rucaparib in patients with ovarian cancer. Progression-free survival (PFS) was evaluated in the maintenance setting for niraparib and olaparib, resulting in a PFS of 21.0 months and 8.4 months, respectively. Olaparib and rucaparib were evaluated in the treatment setting, producing a PFS of 9.4 months and 12.8 months, respectively. PFS was higher in patients with
conclusionPARP inhibitors appear to be a safe and effective new option in the treatment and maintenance of relapsed, advanced
Indexed as
Identifiers
30186027PMC6110640What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.